Jazz Pharmaceuticals plc (JAZZ) Operating Margin
- Operating margin · 12 months: Value 19.49%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 19.49% | Operating income / revenue. Period ending 2026-06-30. $896.86M ÷ $4.60B × 100 ≈ 19.49% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 896.86M USD | Operating Income (Loss) |
| Revenue | 4.60B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 1.68B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $896.86M | $4.60B | (m) | (m) | $1.68B | 19.49% |
| 2026-03-31 | $-37.74M | $4.44B | (m) | (m) | $1.65B | -0.85% |
| 2025-12-31 | $-430.24M | $4.27B | (m) | (m) | $1.81B | -10.08% |
| 2025-09-30 | $-494.00M | $4.16B | (m) | (m) | $1.77B | -11.88% |
| 2025-06-30 | $-291.30M | $4.09B | (m) | (m) | $1.57B | -7.13% |
| 2025-03-31 | $594.53M | $4.06B | (m) | (m) | $1.55B | 14.63% |
| 2024-12-31 | $716.63M | $4.07B | (m) | (m) | $1.39B | 17.61% |
| 2024-09-30 | $648.36M | $3.99B | (m) | (m) | $1.41B | 16.24% |
| 2024-06-30 | $560.54M | $3.91B | (m) | (m) | $1.39B | 14.34% |
| 2024-03-31 | $518.73M | $3.84B | (m) | (m) | $1.40B | 13.50% |
| 2023-12-31 | $578.58M | $3.83B | (m) | (m) | $1.34B | 15.09% |
| 2023-09-30 | $192.70M | $3.79B | (m) | (m) | $1.33B | 5.08% |
| 2023-06-30 | $45.07M | $3.76B | (m) | (m) | $1.38B | 1.20% |
| 2023-03-31 | $-27.02M | $3.74B | (m) | (m) | $1.41B | -0.72% |
| 2022-12-31 | $-65.53M | $3.66B | (m) | (m) | $1.42B | -1.79% |
| 2022-09-30 | $247.24M | $3.58B | (m) | (m) | $1.43B | 6.90% |
| 2022-06-30 | $250.84M | $3.48B | (m) | (m) | $1.44B | 7.21% |
| 2022-03-31 | $95.71M | $3.30B | (m) | (m) | $1.50B | 2.90% |
| 2021-12-31 | $170.28M | $3.09B | (m) | (m) | $1.45B | 5.50% |
| 2021-09-30 | $294.31M | $2.86B | (m) | (m) | $1.30B | 10.28% |
| 2021-06-30 | $462.15M | $2.63B | (m) | (m) | $1.14B | 17.60% |
| 2021-03-31 | $729.87M | $2.44B | (m) | (m) | $906.34M | 29.96% |
| 2020-12-31 | $378.07M | $2.36B | (m) | (m) | $854.23M | 16.00% |
| 2020-09-30 | $265.90M | $2.28B | (m) | (m) | $821.34M | 11.66% |
| 2020-06-30 | $202.80M | $2.22B | (m) | (m) | $792.79M | 9.15% |
| 2020-03-31 | $208.96M | $2.19B | (m) | (m) | $777.39M | 9.55% |
| 2019-12-31 | $532.37M | $2.16B | (m) | $299.73M | $736.94M | 24.63% |
| 2019-09-30 | $656.18M | $2.06B | (m) | $259.00M | $684.53M | 31.91% |
| 2019-06-30 | $711.86M | $1.99B | (m) | $230.31M | $661.70M | 35.81% |
| 2019-03-31 | $660.77M | $1.95B | (m) | $224.05M | $644.26M | 33.81% |
| 2018-12-31 | $614.84M | $1.89B | (m) | $226.62M | $683.53M | 32.52% |
| 2018-09-30 | $570.99M | $1.85B | (m) | $235.95M | $664.72M | 30.85% |
| 2018-06-30 | $468.67M | $1.79B | (m) | $232.16M | $633.37M | 26.13% |
| 2018-03-31 | $480.51M | $1.69B | (m) | $216.18M | $607.11M | 28.48% |
| 2017-12-31 | $528.84M | $1.62B | (m) | $198.44M | $544.16M | 32.67% |
| 2017-09-30 | $553.14M | $1.58B | (m) | $176.60M | $528.25M | 35.03% |
| 2017-06-30 | $602.94M | $1.54B | (m) | $177.04M | $528.09M | 39.12% |
| 2017-03-31 | $606.63M | $1.53B | (m) | $175.97M | $518.38M | 39.70% |
| 2016-12-31 | $591.65M | $1.49B | (m) | $162.30M | $502.89M | 39.76% |
| 2016-09-30 | $532.78M | $1.43B | (m) | $147.59M | $501.31M | 37.20% |
| 2016-06-30 | $528.06M | $1.40B | (m) | $150.58M | $480.98M | 37.75% |
| 2016-03-31 | $512.62M | $1.35B | (m) | $139.32M | $465.50M | 37.93% |
| 2015-12-31 | $508.22M | $1.32B | (m) | $135.25M | $449.12M | 38.36% |
| 2015-09-30 | $531.51M | $1.31B | (m) | $130.36M | $429.26M | 40.51% |
| 2015-06-30 | $458.01M | $1.28B | (m) | $102.00M | $418.71M | 35.84% |
| 2015-03-31 | $379.00M | $1.24B | (m) | $94.25M | $412.14M | 30.68% |
| 2014-12-31 | $195.59M | $1.17B | (m) | $85.18M | $406.11M | 16.68% |
| 2014-09-30 | $160.17M | $1.08B | (m) | $79.42M | $381.72M | 14.82% |
| 2014-06-30 | $202.69M | $1.01B | (m) | $68.82M | $363.19M | 20.15% |
| 2014-03-31 | $205.47M | $923.11M | (m) | $57.98M | $340.14M | 22.26% |
| 2013-12-31 | $340.31M | $872.42M | (m) | $46.62M | $304.30M | 39.01% |
| 2013-09-30 | $313.19M | $820.35M | (m) | $40.09M | $284.38M | 38.18% |
| 2013-06-30 | $267.93M | $763.71M | (m) | $34.19M | $270.34M | 35.08% |
| 2013-03-31 | $230.29M | $679.69M | (m) | $27.27M | $250.05M | 33.88% |
| 2012-12-31 | $197.84M | $585.98M | (m) | $20.48M | $223.88M | 33.76% |
| 2012-09-30 | $168.13M | $485.81M | (m) | $16.96M | $198.89M | 34.61% |
| 2012-06-30 | $140.01M | $394.78M | (m) | $13.32M | $174.57M | 35.47% |
| 2012-03-31 | $138.41M | $329.81M | (m) | $14.38M | $136.02M | 41.97% |
| 2011-12-31 | $127.83M | $272.28M | (m) | $14.12M | $108.94M | 46.95% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $189.49M | (m) | (m) | (m) | (m) |
| 2010-12-31 | $57.79M | $173.78M | (m) | $25.61M | $69.00M | 33.25% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $15.93M | $128.45M | (m) | $36.56M | $58.65M | 12.40% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |